Athira Pharma (NASDAQ:ATHA – Get Rating) released its quarterly earnings data on Thursday. The company reported ($0.56) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($0.01), MarketWatch Earnings reports.
Shares of ATHA traded up $0.32 during mid-day trading on Friday, reaching $8.28. 241,700 shares of the company were exchanged, compared to its average volume of 274,963. Athira Pharma has a 52 week low of $7.56 and a 52 week high of $23.64. The stock has a market capitalization of $311.49 million, a PE ratio of -4.79 and a beta of 3.25. The business has a 50 day simple moving average of $11.01 and a two-hundred day simple moving average of $11.72.
In related news, Director Kelly A. Romano acquired 8,000 shares of the stock in a transaction dated Thursday, March 31st. The stock was bought at an average cost of $13.11 per share, for a total transaction of $104,880.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 14.90% of the stock is owned by company insiders.
Several analysts recently weighed in on the company. JMP Securities reaffirmed a “buy” rating and issued a $51.00 price objective on shares of Athira Pharma in a research note on Friday, March 25th. Zacks Investment Research lowered Athira Pharma from a “buy” rating to a “hold” rating in a research note on Friday, April 22nd. BTIG Research started coverage on Athira Pharma in a research report on Tuesday. They issued a “buy” rating and a $33.00 target price for the company. Finally, Berenberg Bank started coverage on Athira Pharma in a research report on Thursday, April 21st. They issued a “buy” rating and a $33.00 target price for the company. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $29.40.
About Athira Pharma (Get Rating)
Athira Pharma, Inc, a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and stop neurodegradation. Its lead product candidate is ATH-1017, a blood brain barrier-penetrating, small hepatocyte growth factor/MET activator that is in LIFT-AD Phase II/III and ACT-AD Phase II clinical trials for the treatment of mild-to-moderate Alzheimer's disease, as well as in clinical development for Parkinson's disease.
- Get a free copy of the StockNews.com research report on Athira Pharma (ATHA)
- The Three Most Upgraded Stocks You Can Buy Now
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
Receive News & Ratings for Athira Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athira Pharma and related companies with MarketBeat.com's FREE daily email newsletter.